Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine monotherapy in HIV-HBV coinfected patients
NL-OMON32543Phase 4Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telbivudine in Chronic Hepatitis B (CHB), sponsored by University Medical Center Utrecht. Primary endpoint: Resistance development. Planned start Sep 2008; status: withdrawn.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON32543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32543.